Compare IPCA Labs with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs CADILA HEALTHCARE - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS CADILA HEALTHCARE IPCA LABS/
CADILA HEALTHCARE
 
P/E (TTM) x 23.1 14.8 155.5% View Chart
P/BV x 4.5 2.9 154.5% View Chart
Dividend Yield % 0.1 1.4 7.4%  

Financials

 IPCA LABS   CADILA HEALTHCARE
EQUITY SHARE DATA
    IPCA LABS
Mar-18
CADILA HEALTHCARE
Mar-18
IPCA LABS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs695558 124.6%   
Low Rs400362 110.7%   
Sales per share (Unadj.) Rs260.2116.3 223.7%  
Earnings per share (Unadj.) Rs19.017.9 106.2%  
Cash flow per share (Unadj.) Rs33.123.1 142.9%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.20.8 24.0%  
Book value per share (Unadj.) Rs213.085.4 249.4%  
Shares outstanding (eoy) m126.201,023.74 12.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.0 53.2%   
Avg P/E ratio x28.925.7 112.2%  
P/CF ratio (eoy) x16.619.9 83.4%  
Price / Book Value ratio x2.65.4 47.8%  
Dividend payout %5.319.6 26.9%   
Avg Mkt Cap Rs m69,120470,664 14.7%   
No. of employees `00013.311.8 112.1%   
Total wages/salary Rs m7,35918,545 39.7%   
Avg. sales/employee Rs Th2,477.410,072.7 24.6%   
Avg. wages/employee Rs Th555.21,569.1 35.4%   
Avg. net profit/employee Rs Th180.61,547.7 11.7%   
INCOME DATA
Net Sales Rs m32,836119,049 27.6%  
Other income Rs m4181,132 36.9%   
Total revenues Rs m33,254120,181 27.7%   
Gross profit Rs m4,50528,475 15.8%  
Depreciation Rs m1,7775,388 33.0%   
Interest Rs m240911 26.4%   
Profit before tax Rs m2,90523,308 12.5%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5115,644 9.1%   
Profit after tax Rs m2,39418,292 13.1%  
Gross profit margin %13.723.9 57.4%  
Effective tax rate %17.624.2 72.6%   
Net profit margin %7.315.4 47.5%  
BALANCE SHEET DATA
Current assets Rs m19,45582,005 23.7%   
Current liabilities Rs m10,07660,720 16.6%   
Net working cap to sales %28.617.9 159.8%  
Current ratio x1.91.4 143.0%  
Inventory Days Days9873 133.8%  
Debtors Days Days6798 68.1%  
Net fixed assets Rs m20,26083,703 24.2%   
Share capital Rs m2521,024 24.6%   
"Free" reserves Rs m26,63386,421 30.8%   
Net worth Rs m26,88687,445 30.7%   
Long term debt Rs m2,34025,551 9.2%   
Total assets Rs m41,173180,653 22.8%  
Interest coverage x13.126.6 49.3%   
Debt to equity ratio x0.10.3 29.8%  
Sales to assets ratio x0.80.7 121.0%   
Return on assets %6.410.6 60.2%  
Return on equity %8.920.9 42.6%  
Return on capital %10.822.0 48.9%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64242,683 36.6%   
Fx outflow Rs m4,88411,242 43.4%   
Net fx Rs m10,75931,441 34.2%   
CASH FLOW
From Operations Rs m3,4119,193 37.1%  
From Investments Rs m-1,354-9,737 13.9%  
From Financial Activity Rs m-1,304515 -253.2%  
Net Cashflow Rs m753-29 -2,597.2%  

Share Holding

Indian Promoters % 45.9 74.8 61.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 8.3 137.3%  
FIIs % 25.3 5.9 428.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 11.0 158.2%  
Shareholders   36,892 44,069 83.7%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON   

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS